Syntaxin and Allergan push AGN-214868 into Phase II trials

Syntaxin has announces that its partner Allergan has initiated two Phase II trials to evaluate the safety and efficacy of its re-targeted endopeptidase drug candidate AGN-214868. The Phase II trials will be focused on patients with post herpetic neuralgia (and overactive bladder. With the initiation of Phase II trials, Syntaxin’s drug technology platform reached a significant point of development and triggered an undisclosed milestone payment. Allergan provided an update in its Q4 2010 earnings call on 2nd February 2011. AGN-214868 was discovered under the collaboration using Syntaxin’s discovery platform. Under this agreement, Allergan is responsible for the clinical development, marketing and sales of identified drug candidates. Syntaxin receives milestone payments and royalties on product sales.